A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX

References

• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi:10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int J Mol Sci. 2020;22(1):130. doi:10.3390/ijms22010130
   PubMed Web of Science ®Google Scholar
• Johdi NA, Sukor NF. Colorectal cancer immunotherapy: options and strategies. Front Immunol. 2020;11:1624. doi:10.3389/fimmu.2020.01624
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74(2):106–133. doi:10.1016/j.critrevonc.2010.01.010
   PubMed Web of Science ®Google Scholar
• McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–1557. doi:10.2174/0929867324666170111152436
   PubMed Web of Science ®Google Scholar
• Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol. 2000;11(Suppl 3):29–36. doi:10.1093/annonc/11.suppl_3.29
   Google Scholar
• Adson MA, van Heerden JA, Adson MH, Wagner JS. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119:647–651. doi:10.1001/archsurg.1984.01390180015003
   PubMed Web of Science ®Google Scholar
• Coppa GF, Eng K, Ranson JH, Gouge TH, Localio SA. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg. 1985;202:203–208. doi:10.1097/00000658-198508000-00010
   Web of Science ®Google Scholar
• Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–1246. doi:10.1002/bjs.1800771115
   PubMed Web of Science ®Google Scholar
• Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29.
   PubMed Web of Science ®Google Scholar
• Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885–1893. doi:10.1200/JCO.1990.8.11.1885
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047. doi:10.1016/S0140-6736(00)02034-1
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947. doi:10.1200/JCO.2000.18.16.2938
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147. doi:10.1200/JCO.2000.18.1.136
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc ASCO. 2002;21:128a.
   Google Scholar
• Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO. 2002;21:129a.
   Google Scholar
• Kohne CH, Van Cutsem E, Wils J, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc ASCO. 2003;22:254.
   Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345. doi:10.1056/NEJMoa033025
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. doi:10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65. doi:10.1200/JCO.2003.10.066
   PubMed Web of Science ®Google Scholar
• Suzuki N, Suzuki N, Tomochika S, et al. A case of conversion surgery for unresectable colorectal liver metastases, following effective combined chemotherapy with molecular targeting agents. Gan to Kagaku Ryoho. 2017;44(12):1272–1274.
   Google Scholar
• Watanabe K, Kawahara H, Enomoto H, et al. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. Anticancer Res. 2013;33:4029–4032.
   Web of Science ®Google Scholar
• Suetsugu T, Matsuhashi N, Takahashi T, et al. Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases. Mol Clin Oncol. 2018;9(6):587–591. doi:10.3892/mco.2018.1742
   Web of Science ®Google Scholar
• Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology program by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636–1646. doi:10.1016/j.jtho.2020.07.014
   PubMed Web of Science ®Google Scholar
• Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med. 2020;8(18):1187. doi:10.21037/atm-20-6063
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour -associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi:10.1038/nature22396
   PubMed Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318. doi:10.1016/j.biopha.2018.11.105
   PubMed Web of Science ®Google Scholar
• Wang X, Duanmu J, Fu X, Li T, Jiang Q. Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. J Transl Med. 2020;18(1):324. doi:10.1186/s12967-020-02491-w
   Web of Science ®Google Scholar
• Gou Q, Dong C, Xu H, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955. doi:10.1038/s41419-020-03140-2
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu HX, Lin WH, et al. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Med. 2021;19(1):26. doi:10.1186/s12916-020-01899-x
   Web of Science ®Google Scholar
• Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794–802. doi:10.1038/s43018-021-00232-6
   PubMedGoogle Scholar
• Sun H, Liu SY, Zhou JY, et al. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine. 2020;60:102990. doi:10.1016/j.ebiom.2020.102990
   PubMed Web of Science ®Google Scholar